Buffalo, NY, April 26, 2014 --(PR.com
)-- NanoAxis LLC has announced that it has become a shareholder in Canadian based company, NanoApps Medical Inc., to assist in accelerating nanomedical product development and commercialization.
NanoApps Medical Inc. is actively collaborating with both Canadian and US based (Mayo Clinic, Rochester, MN, and Louisiana State University, Baton Rouge, LA) researchers, to transition several advanced nanomedical diagnostic and drug delivery platforms from envisaged concepts to beneficial efficacious products.
Lead product development applications encompass a rapid throughput biomarker detection platform, which utilizes patient breath as the medium, and the creation of a novel hybrid nanomedical platform (DuflexxTM) to enable diagnostic imaging, therapeutic hyperthermia, and precision drug delivery.
"NanoApps Medical Inc. is a company we see with the right vision. They are in line with what NanoAxis wants to accomplish in terms of changing multiple medical paradigms via nanotechnology and nanomedicine. As shareholder and partner, NanoAxis will help guide NanoApps Medical in accelerating nanomedicine product development for commercial use worldwide” –Dr. Krishnan Chakravarthy MD, PhD, Chairman and CEO of NanoAxis.
Frank Boehm, CEO of NanoApps Medical Inc., offers, “I am indeed very honored and excited to partner with NanoAxis. Through our considerable combined expertise and collaborative efforts, I believe that we will progress significantly as a united synergetic front toward the potential development of unprecedented advanced nanomedical diagnostic and therapeutic devices and systems for global benefit.”
NanoAxis, LLC (www.nanoaxisllc.com) is a nanotechnology company that utilizes nanomaterials for the development of new nanomedicine applications across both diagnostic and therapeutic domains. We work with various academic and industrial customers by offering them practical and cost-effective solutions to their specific problems as relates to the use of nanomaterials for various life science applications. Areas of biological interest and current product platforms include the creation of new medical devices, gene therapy applications, and targeted drug delivery by employing unique nanoparticle based technologies.
About NanoApps Medical, Inc.
NanoApps Medical, Inc. was incorporated in 2009, with the aim of developing advanced, innovative, efficacious and cost effective nanomedical diagnostic and therapeutic components, devices and systems for the benefit of individuals globally. The company will strive for ideals that “encompass the minimization or negation of invasiveness and negative side effects, while providing maximum benefits and positive outcomes for patients. The big sky aim of the company will be to contribute in a significant way to facilitating affordable access to advanced nanomedical procedures for those individuals in remote and developing regions of the world, as well as those in developed regions.”